Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Enterprise Value (2018 - 2025)

Historic Enterprise Value for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to -$466.2 million.

  • TransMedics' Enterprise Value fell 4123.25% to -$466.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.2 million, marking a year-over-year decrease of 4123.25%. This contributed to the annual value of -$336.6 million for FY2024, which is 1473.16% up from last year.
  • TransMedics' Enterprise Value amounted to -$466.2 million in Q3 2025, which was down 4123.25% from -$400.6 million recorded in Q2 2025.
  • TransMedics' Enterprise Value's 5-year high stood at -$58.1 million during Q2 2022, with a 5-year trough of -$582.2 million in Q2 2023.
  • Moreover, its 5-year median value for Enterprise Value was -$310.1 million (2025), whereas its average is -$269.3 million.
  • In the last 5 years, TransMedics' Enterprise Value skyrocketed by 4825.52% in 2022 and then crashed by 90237.59% in 2023.
  • Over the past 5 years, TransMedics' Enterprise Value (Quarter) stood at -$92.5 million in 2021, then tumbled by 117.61% to -$201.2 million in 2022, then plummeted by 96.25% to -$394.8 million in 2023, then rose by 14.73% to -$336.6 million in 2024, then crashed by 38.48% to -$466.2 million in 2025.
  • Its Enterprise Value was -$466.2 million in Q3 2025, compared to -$400.6 million in Q2 2025 and -$310.1 million in Q1 2025.